![]() UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | Livzon Pharmaceutical Group Livzon Pharmaceutical Group (丽珠医药集团股份有限公司, 丽珠医药) is a pharmaceutical company that engages in the development and production of active pharmaceutical ingredients, biological drugs, diagnostic reagents, and other products. | Alembic Pharmaceuticals Alembic Pharmaceuticals is a company that develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and intermediates | |
Founding Date | Founding Date 1928 | Founding Date 1985 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | Locations Zhuhai, CN HQ Chengdu, CN Qingyuan, CN Shanghai, CN Shaoguan, CN Shenzhen, CN Zhuhai, CN | Locations Vadodara, IN HQ Baska, IN Mumbai, IN Namthang, IN Vadodara, IN Vadodara, IN |
Employees | Employees 9,052 | Employees 9,067 | Employees 14,858 |
Valuation ($) | Valuation ($) 34.3 b | Valuation ($) 4.2 b | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) €7.4b (FY, 2025) | Revenue (est.) ¥11.7b (FY, 2025) | Revenue (est.) ₹73.4b (FY, 2026) |
Cost of goods | Cost of goods €1.4b (FY, 2025) | Cost of goods ¥4.1b (FY, 2025) | Cost of goods ₹19.8b (FY, 2026) |
Gross profit | Gross profit €7.2b (FY, 2025) | Gross profit ¥7.8b (FY, 2025) | Gross profit ₹54.1b (FY, 2026) |
Net income | Net income €1.6b (FY, 2025) | Net income ¥2.4b (FY, 2025) | Net income ₹6.7b (FY, 2026) |
Livzon Pharmaceutical Group (丽珠医药集团股份有限公司, 丽珠医药) is a pharmaceutical company that engages in the development and production of active pharmaceutical ingredients, biological drugs, diagnostic reagents, and other products.
View companyAlembic Pharmaceuticals is a company that develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and intermediates
View company